|
1
|
Angus DC, Linde-Zwirble WT, Lidicker J,
Clermont G, Carcillo J and Pinsky MR: Epidemiology of severe sepsis
in the United States: analysis of incidence, outcome, and
associated costs of care. Crit Care Med. 29:1303–1310. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lawrence K: Pediatric sepsis and
multiorgan dysfunction syndrome: progress and continued challenges.
Crit Care Nurs Clin North Am. 23:323–337. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bone RC, Sibbald WJ and Sprung CL: The
ACCP/SCCM consensus conference on sepsis and organ failure. Chest.
101:1481–1483. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Davies MG and Hagen PO: Systemic
inflammatory response syndrome. Br J Surg. 84:920–935. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shimada H, Moriwaki Y, Kurosawa H, et al:
Inflammatory mediator and organ dysfunction syndrome. Nippon Geka
Gakkai Zasshi. 99:490–496. 1998.In Japanese.
|
|
6
|
Bone RC: Immunologic dissonance: a
continuing evolution in our understanding of the systemic
inflammatory response syndrome (SIRS) and the multiple organ
dysfunction syndrome (MODS). Ann Intern Med. 125:680–687. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Volk HD, Reinke P, Krausch D, et al:
Monocyte deactivation - rationale for a new therapeutic strategy in
sepsis. Intensive Care Med. 22(Suppl 4): S474–S481. 1996.
View Article : Google Scholar
|
|
8
|
Mentula P, Kylänpää-Bäck ML, Kemppainen E,
et al: Decreased HLA (human leucocyte antigen)-DR expression on
peripheral blood monocytes predicts the development of organ
failure in patients with acute pancreatitis. Clin Sci (Lond).
105:409–417. 2003. View Article : Google Scholar
|
|
9
|
Schefold JC: Measurement of monocytic
HLA-DR (mHLA-DR) expression in patients with severe sepsis and
septic shock: assessment of immune organ failure. Intensive Care
Med. 36:1810–1812. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hotchkiss RS, Swanson PE, Freeman BD, et
al: Apoptotic cell death in patients with sepsis, shock, and
multiple organ dysfunction. Crit Care Med. 27:1230–1251. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hotchkiss RS, Tinsley KW, Swanson PE, et
al: Depletion of dendritic cells, but not macrophages, in patients
with sepsis. J Immunol. 168:2493–2500. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Boomer JS, To K, Chang KC, et al:
Immunosuppression in patients who die of sepsis and multiple organ
failure. JAMA. 306:2594–2605. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Reddy RC, Chen GH, Tekchandani PK and
Standiford TJ: Sepsis-induced immunosuppression: from bad to worse.
Immunol Res. 24:273–287. 2001. View Article : Google Scholar
|
|
14
|
Monneret G, Debard AL, Venet F, et al:
Marked elevation of human circulating CD4+CD25+ regulatory T cells
in sepsis-induced immunoparalysis. Crit Care Med. 31:2068–2071.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiangyang L, Qian L, Xiaohong W, et al:
Changes of spleen dendritic cells in the terminal stage of multiple
organ dysfunction syndrome. Acta Biomed. 82:146–153. 2011.
|
|
16
|
Shurin MR, Pandharipande PP, Zorina TD, et
al: FLT3 ligand induces the generation of functionally active
dendritic cells in mice. Cell Immunol. 179:174–184. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sakabe H, Kimura T, Zeng Z, et al:
Haematopoietic action of flt3 ligand on cord blood-derived
CD34-positive cells expressing different levels of flt3 or c-kit
tyrosine kinase receptor: comparison with stem cell factor. Eur J
Haematol. 60:297–306. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shaw SG, Maung AA, Steptoe RJ, Thomson AW
and Vujanovic NL: Expansion of functional NK cells in multiple
tissue compartments of mice treated with Flt3-ligand: implications
for anti-cancer and anti-viral therapy. J Immunol. 161:2817–2824.
1998.PubMed/NCBI
|
|
19
|
Wysocka M, Montaner LJ and Karp CL: Flt3
ligand treatment reverses endotoxin tolerance-related
immunoparalysis. J Immunol. 174:7398–7402. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Flohé SB, Agrawal H, Schmitz D, Gertz M,
Flohé S and Schade FU: Dendritic cells during polymicrobial sepsis
rapidly mature but fail to initiate a protective Th1-type immune
response. J Leukoc Biol. 79:473–481. 2006. View Article : Google Scholar
|
|
21
|
Fujita S, Seino K, Sato K, et al:
Regulatory dendritic cells act as regulators of acute lethal
systemic inflammatory response. Blood. 107:3656–3664. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wallet MA, Sen P and Tisch R:
Immunoregulation of Dendritic Cells. Clin Med Res. 3:166–175. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Volman TJ, Hendriks T and Goris RJ:
Zymosan induced generalized inflammation: experimental studies into
mechanisms leading to multiple organ dysfunction syndrome. Shock.
23:291–297. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang M, Tang H, Guo Z, et al: Splenic
stroma drives mature dendritic cells to differentiate into
regulatory dendritic cells. Nat Immunol. 5:1124–1133. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tan C, Reddy V, Dannull J, et al: Impact
of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion
vaccine efficacy in a murine melanoma model. J Transl Med.
11:1482013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fan X, Ye M, Xue B, Ke Y, Wong CK and Xie
Y: Human dendritic cells engineered to secrete interleukin-18
activate MAGE-A3-specific cytotoxic T lymphocytes in vitro. Immunol
Invest. 41:469–483. 2012. View Article : Google Scholar : PubMed/NCBI
|
